CTIS2023-503484-42-00招募中1 期
A Phase 1/2 Study of BMS-986449 Alone and in Combination with Nivolumab in Participants with Advanced Solid Tumors - CA120-1001
Bristol-Myers Squibb Services Unlimited Company0 个研究点目标入组 98 人开始时间: 2023年6月12日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 98
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Participants =18 years of age with histologically or cytologically confirmed locally advanced unresectable, metastatic, or recurrent select solid tumor - Part 1A, participants may have a solid malignancy of any histology - Part1B is restricted to participants with NSCLC - Part 1C is restricted to participants with TNBC, Participants must have received, be refractory to, ineligible for, or intolerant of existing therapy(ies) known to provide clinical benefit for their condition., Participants must have measurable disease per RECIST v 1.1., Tumor biopsy must be obtained for all participants (unless medically precluded)
排除标准
- •Participants with active, known or suspected autoimmune disease., Participants with a condition requiring systemic treatment with corticosteroids within 14 days or other immunosuppressive medications within 30 days of randomization, Participant with prior organ or tissue allograft, Participants with history of = Gr 3 toxicity related to prior T cell agonist or checkpoint inhibitor therapy (eg, anti-CTLA-4, or anti-PD-1/PD-L1 treatment, or any other antibody or drug specifically targeting T cell co-stimulation or other immune checkpoint pathways)., Participants with any significant acute or chronic medical illness which would interfere with study intervention or follow-up in the opinion of the investigator., Participants with untreated or symptomatic CNS metastases or leptomeningeal metastases.
研究者
相似试验
进行中（未招募）
1 期
A Phase 1/2 Study of BMS-986408 with and without Nivolumab or Nivolumab and Ipilimumab in Participants with Solid TumorsAdvanced Solid TumoursMedDRA version: 21.0Level: LLTClassification code: 10049280Term: Solid tumour Class: 10029104CTIS2022-500823-61-00Bristol-Myers Squibb International Corporation136
招募中
1 期
A Phase 1b/2 Study of BMS-986442 with Nivolumab with or without Chemotherapy in Solid Tumors and Non-small Cell Lung CancerSolid Tumor, Non-small cell lung cancerMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2022-503108-26-00Bristol-Myers Squibb Services Unlimited Company245
进行中（未招募）
1 期
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimumab in Patients with Advanced CancersEUCTR2018-000340-26-DEBristol-Myers Squibb International Corporation800
进行中（未招募）
1 期
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimumab in Patients with Advanced CancersAdvanced solid tumorsMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2023-509061-20-00Bristol Myers Squibb International Corporation639
进行中（未招募）
1 期
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab or Nivolumab plus Ipilimumab in Patients with Advanced CancersAdvanced CancersMedDRA version: 21.1Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 100000004864EUCTR2018-000340-26-PLBristol-Myers Squibb International Corporation800